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DOI 10.1016/j.ccr.2010.06.014SUMMARYAnti-HER2/neu antibody therapy is reported to mediate tumor regression by interrupting oncogenic signals
and/or inducing FcR-mediated cytotoxicity. Here, we demonstrate that the mechanisms of tumor regression
by this therapy also require the adaptive immune response. Activation of innate immunity and T cells, initiated
by antibody treatment, was necessary. Intriguingly, the addition of chemotherapeutic drugs, although
capable of enhancing the reduction of tumor burden, could abrogate antibody-initiated immunity leading
to decreased resistance to rechallenge or earlier relapse. Increased influx of both innate and adaptive
immune cells into the tumor microenvironment by a selected immunotherapy further enhanced subsequent
antibody-induced immunity, leading to increased tumor eradication and resistance to rechallenge. This study
proposes a model and strategy for anti-HER2/neu antibody-mediated tumor clearance.INTRODUCTION
The human epidermal growth factor receptor 2 (HER2, HER2/
neu, or ErbB-2) is overexpressed in 20%–30% of breast carci-
nomas and is associated with aggressive disease, a high recur-
rence rate, and reduced patient survival (Hudis, 2007; Kiessling
et al., 2002; Meric-Bernstam and Hung, 2006; Slamon et al.,
1987). The use of trastuzumab (Herceptin), a humanized mono-
clonal antibody that binds the extracellular, juxtamembranal
domain of HER2, has proved to be an effective treatment in
animal and human studies (Hudis, 2007; Moasser, 2007). Many
groups have demonstrated that anti-HER2/neu antibody canSignificance
Although anti-HER2/neu antibody is an effective adjuvant the
even after prolonged treatment. Current understanding holds
induces FcR-mediated cytotoxicity. This study reveals that t
also depends on adaptive immunity. Furthermore, this study d
whereby danger signals are required to mobilize and activat
increase tumor clearance. However, antibody-initiated tumor
mens. This study has important clinical impact because variou
body treatment.
160 Cancer Cell 18, 160–170, August 17, 2010 ª2010 Elsevier Inc.efficiently stop or slow the growth of HER2/neu+ tumors in vitro
(Hudis, 2007; Kiessling et al., 2002; Meric-Bernstam and Hung,
2006). Growth inhibition is mainly due to the induction of G1
cell cycle arrest and is closely tied to increased p27Kip1 expres-
sion, and reduced cyclin E expression (Le et al., 2005; Mittendorf
et al., 2010). In addition, antibody treatment was shown to
inhibit the ability of tumor cells to repair damaged DNA (Pegram
et al., 1999). The combination of antibody treatment with
multiple chemotherapeutic agents showed additive and syner-
gistic effects in in vitro studies and in vivo xenograft tumor
models (Pegram et al., 1999; Pegram et al., 2004). As a result,
interference with HER2 oncogenic signaling and increasedrapy targeting HER2+ breast cancers, relapse often occurs
that this antibody therapy interrupts oncogenic signals and
he therapeutic effect of anti-HER2/neu antibody treatment
emonstrates an interesting antibody-mediated mechanism
e innate cells and prime the adaptive immune system for
regression can be impaired by certain chemotherapy regi-
s chemotherapy drugs have been used before or after anti-
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Figure 1. Anti-Neu Antibody Has Limited
Effect In Vitro but Has Strong Effect Against
Tumor In Vivo
(A) WT BALB/c mice (n = 5/group) were injected
s.c. with 5 3 105 TUBO cells and treated with
100 mg of anti-neu (a-neu) or isotype control (Ctrl)
antibody on days 14 and 21. The tumor growth
was measured and compared twice a week.
***p < 0.005 compared with isotype control group
after day 23. One of five representative experi-
ments is shown.
(B) TUBO cells (1 3 105 cells/well) were plated
in a monolayer and incubated with Erlotinib
(1–4 mmol/l) or anti-neu antibody (0.3–3 mg/ml).
Control groups received isotype-control antibody
(Ctrl). Relative proliferation, reflected by metabolic
activity, was evaluated at indicated times by MTT
assay and graphed as percent of isotype control.
Mean ± SD; *p < 0.05; **p < 0.005 compared
with isotype control. One of two representative
experiments is shown.
(C) TUBO-bearing BALB/cmice (n = 5/group) were
treated four times with 100 mg of anti-neu antibody
(a-neu) every other day and with 500 mg of Erlotinib
every day for 7 days from day 18. *p < 0.05
compared with the control group from day 33;
**p < 0.01 compared with erlotinib-treated group
after day 26. One of two representative experi-
ments is shown.
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Bridging Innate and Adaptive Immunity by Anti-Neususceptibility to chemotherapy-induced apoptosis (chemosen-
sitization) have been proposed as the central mechanisms
responsible for the clinical efficacy of trastuzumab (Hudis,
2007; Moasser, 2007; Pegram et al., 2004). Based on the con-
vincing preclinical studies, clinical trials were conducted and
demonstrated the benefits of combining chemotherapy adminis-
tration with trastuzumab (Hudis, 2007; Piccart-Gebhart et al.,
2005; Romond et al., 2005). Despite of the initial clinical success
of antibody plus chemotherapy treatment for Her2+ tumors,
relapse has been reported after cessation of this treatment.
Considering reports that inhibition of oncogenic signals by
anti-HER2/neu antibody controls tumor growth in vitro, it was
surprising that the therapeutic effect of this antibody was dimin-
ished in the absence of Fc receptor (FcR) signaling in vivo
(Clynes et al., 2000). The role of FcRs in the efficacy of antibody
treatment is further supported by evidence that Fcr polymor-
phisms are associated with the clinical outcome in breast cancer
patients (Musolino et al., 2008). These data raise the possibility
that antibody-dependent cellular cytotoxicity (ADCC) may play
a major role in the antitumor effects of antibody therapy. Consis-
tently, an increase of tumor-infiltrating leukocytes, especially
FcR+ cells such as NK cells, has been observed in tumor tissue
after antibody treatment (Arnould et al., 2006; Varchetta et al.,
2007). Furthermore, it was reported that patients with partial or
complete remission after antibody treatment had higher in situ
infiltration of leukocytes and an increased capacity to mediate
in vitro ADCC activity (Gennari et al., 2004). Endogenous anti-
HER2 antibodies after vaccine can be detected in some patients
and can effectively suppress HER2 kinase activity and down-
stream signaling to inhibit the transformed phenotype of HER2-
expressing tumor cells (Montgomery et al., 2005). However,
most models, including xenografts used for preclinical evalua-tion, fail to account for adaptive immunity in the antibody-
mediated therapeutic effect. Therefore, the essential role of T
and B cells in anti-HER2/neu antibody-mediated tumor regres-
sion remains unclear.
RESULTS
Adaptive Immunity Is Essential for the Therapeutic
Effect of Antibody Treatment
To evaluate whether targeted antibody treatment of HER2/neu+
breast cancer could reduce tumor burden in syngeneic wild-type
(Wt) mice, we used the well-characterized anti-neu (rat homolog
of human HER2) monoclonal antibody 7.16.4 (Zhang et al.,
1999). This antibody competes with 4D5 (the original mouse
anti-HER2/neu antibody that was humanized to trastuzumab)
for binding to human HER2 and inhibition of tumor growth.
BALB/c mice bearing established TUBO tumors, a neu overex-
pressing cell line derived from a spontaneous carcinoma in
neu-transgenic mice (Rovero et al., 2000), were treated with
anti-neu antibody. Impressively, without the addition of chemo-
therapy, the majority (28/35) of Balb/c mice from several exper-
iments rejected tumors completely 4 weeks after treatment,
whereas control Ig-treated mice had to be sacrificed due to large
tumor burden (Figure 1A and Table 1).
To test the relative contribution of HER2/neu signal interfer-
ence with anti-neu antibody-mediated tumor regression, we
compared the efficacy of this antibody to erlotinib, a tyrosine
kinase inhibitor (TKI), in vitro and in vivo. A high dose of anti-
neu antibody slightly inhibited TUBO cell proliferation in vitro
(20%), but effectively reversed the growth of or cleared all
established tumors in vivo (35/35). On the other hand, erlotinib
strongly inhibited TUBO cell proliferation in vitro (>80%) butCancer Cell 18, 160–170, August 17, 2010 ª2010 Elsevier Inc. 161
Table 1. The Therapeutic Effect of Combined Chemotherapy and Antibody Treatment on Tumor Regression and Rechallenge
Chemotherapy
Antibody Dosagea Drugb Dosage Schedulec
Rate of Tumor
Regressiond Rejected/Total (%)
Growth After Rechallenge
Growth/Total (%)e
100 mg 3 2 None 28/35 (80 0/19 (0)f,g
100 mg 3 3 None 20/24 (83%) 0/6 (0)f,g
100 mg 3 4 None 1/5(80) NDf
100 mg 3 2 PTX 60 mg/kg 3 2 3 days after + 10/10 (100) 7/9 (78)f
100 mg 3 2 PTX 40 mg/kg 3 2 3 days after + 10/10 (100) 7/9 (78)f
100 mg 3 2 PTX 10 mg/kg 3 4 3 days after = 4/4 (100) 0/4 (0)f
100 mg 3 2 PTX 40 mg/kg 3 1 1 day before + 12/12 (100) 0/4 (0)f,g
100 mg 3 2 PTX 20 mg/kg 3 1 1 day before + 4/4 (100) 2/4 (50)f,g
100 mg 3 2 CTX 100 mg/kg 3 2 3 days after + 12/20 (60) 2/3 (67)f
100 mg 3 2 DOX 15 mg/kg 3 2 Same day  0/5 (0) NDg
100 mg 3 2 DOX 5 mg/kg 3 2 Same day  0/5 (0) NDg
CTX, cyclophosphamide; DOX, doxorubicin; ND, not determined; PTX, paclitaxel.
a BALB/c mice were implanted with 4–53 105 TUBO cells on day 0. Groups of 5–10 mice were injected i.p. with anti-neu antibody at 5–7 day intervals
starting on day 12 or day 18 after tumor implantation, with or without chemotherapeutics. Tumors were measured twice a week.
bChemotherapeutic used. All drugs were injected i.p.
c Chemotherapeutic administration relative to anti-neu antibody treatment.
d Comparison of the incidence of regression to anti-neu antibody treatment (100 mg 3 2) alone; +, greater than antibody alone; = , similar to antibody
alone; , less than antibody alone.
eOne month after complete tumor regression, tumor-free mice were rechallenged with 2–5 3 106 TUBO cells and tumor growth was monitored for
30 days.
f Experiments were performed in CAS.
g Experiments were performed in UC.
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Figure 2. Antitumor Effect of Antibody Depends on Both FcR and
Adaptive Immune System
(A) TUBO-bearing Fcg receptor KO andWT BALB/c mice (n = 6–8/group) were
treated with 100 mg of anti-neu or isotype control antibody on days 14 and 21.
**p < 0.01 compared with WT isotype control group after day 29. One of three
experiments is shown.
(B) TUBO-bearing Wt and Rag-1/ mice (n = 5–7/group) were treated with
100 mg of anti-neu antibody (a-neu) or isotype control (Ctrl) on days 18 and
25. *p < 0.05; **p < 0.005 compared to isotype control groups of each mouse
strain as (A). One of three experiments is shown. Increase of lymphocytes
inside tumor is seen in Figure S1.
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Bridging Innate and Adaptive Immunity by Anti-Neuweakly impacted tumor growth rates in vivo without reversal of
tumor growth (Figures 1B and 1C). These data support the recent
model that anti-HER2/neu antibody treatment requires ADCC via
FcRs for effective in vivo treatment of human HER2/neu+ tumors
(Clynes et al., 2000). To test whether ADCC is accountable for
this additional reduction of tumor masses in our in vivo model
system, WT and Fcgr KO mice were inoculated with TUBO and
established tumors were treated with 7.16.4. Indeed, the thera-
peutic effect of anti-neu antibody was FcgR-dependent, as
FcgR deficient mice failed to show antibody-induced inhibition
(Figure 2A). Together, using a system modeling human HER2/
neu+ tumor growth, our data consistently support the model
that FcR+ cells are essential for inhibiting or even eradicating
neu+ tumors in response to anti-neu antibody treatment. To
further explore the role of ADCC in anti-neu antibody therapy,
we inoculated Rag-1/ mice with TUBO. Though Rag-1/
mice lack T and B cells, these mice do have a complete popula-
tion of FcR+ innate cells to mediate ADCC. Thus, we expected
these mice to regress established TUBO tumors efficiently after
anti-neu antibody treatment. Although WT mice treated with
anti-neu antibody consistently demonstrate tumor regression,
this antibody treatment had a very limited impact on the growth
of established tumors in Rag-1/ mice (Figure 2B). Although
some Rag-1/ mice displayed delayed tumor growth lasting,
no tumor regression was observed inRag-1/mice (total n = 13)
after antibody treatment. Thus, these data reveal that the innate
immune response alone is not sufficient to mediate the thera-
peutic effect of anti-neu antibody treatment. Therefore, we
considered the role of the adaptive immune response being
essential for antibody-mediated tumor reduction.162 Cancer Cell 18, 160–170, August 17, 2010 ª2010 Elsevier Inc.Anti-Neu Antibody-Induced CTL and Immunological
Memory Are Required for Protection
CD8+ cytotoxic lymphocytes are a major adaptive immune cell
population involved in controlling tumor growth. We observed
increased lymphocytes, especially CD8+ cells, in TUBO tumor
tissues 1–2 weeks after antibody treatment (see Figure S1 avail-
able online). To determine whether CD8+ T cells are essential for
anti-neu antibody-mediated tumor regression, TUBO-bearing
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Figure 3. Therapeutic Effect of Anti-Neu
Antibody Treatment Requires CD8+ Cells
and Induces Memory T Cell Responses
(A) WT BALB/c mice (n = 5–10/group) were
injected s.c. with 5 3 105 TUBO and treated with
100 mg of anti-neu antibody (a-neu) on days 10,
17, and 24. CD8-depleting antibody (YTS169.4.2,
200 mg/mouse) was administered every 3 days,
starting on day 9. *p < 0.05; **p < 0.005 compared
to anti-neu antibody-treated WT mice. One of
three experiments is shown.
(B) Neu Tg F1mice (n = 6/group) were injectedwith
33 105 TUBO cells and treatedwith 100 mg of anti-
neu antibody (a-neu) on days 11 and 18. CD8-
dpeleting antibody (YTS169.4.2, 200 mg/mouse)
was administered on the same days. *p < 0.05
compared to anti-neu antibody-treated group.
One of two experiments is shown. The data from
other CD8-depleting antibodies is shown in
Figure S2.
(C) Tumor-free, antibody-treated BALB/c mice
(n = 14 pooled from two experiments) were
rechallenged s.c. with 5 3 106 TUBO cells on
different site from primary tumor at least 1 month
after complete rejection of primary tumors. All of
mice rejected the secondary tumor. One of two
experiments is shown.
(D) TUBO bearing mice were treated twice with 150ug of either anti-neu (n = 3) or mIgG (n = 3) on days 11 and 18. Mice were sacrificed 12 days after the final
treatment and splenocytes were isolated for ELISPOT analysis as described in Experimental Procedures. ***p < 0.0001.
(E) Splenocytes from neu Tg F1mice (n = 3–5) treated with anti-neu or isotype control antibody were stimulated with 3T3/KB, 3T3/NKB, or TUBO cells. The ratio of
splenocytes to APCwas 10:1. IFN-g–producing cells were enumerated by ELISPOT assay. Results were expressed as number of spots per 106 splenocytes. *p <
0.05; **p < 0.005 compared with isotype control group. One of three experiments is shown for (D) and (E). Increase of tumor infiltrated lymphocytes was also seen
in human samples after antibody treatment (see Figure S2C)
Cancer Cell
Bridging Innate and Adaptive Immunity by Anti-NeuBALB/cmice were treated with an anti-CD8a-depleting antibody
(YTS169.4.2) in conjunction with anti-neu antibody treatment.
Initially, tumors in antibody-treated mice continued to regress,
but relapsed rapidly in the absence of CD8+ T cells (Figure 3A).
Anti-CD8 a antibody had no detectable impact on tumor growth
in control Ig treated mice. In addition, depletion of CD8 a+ cells
using another clone (53.6.7) that has less impact on CD8 a+
DC displayed the same phenotype but antibody-mediated effect
is still dependent on CD8+ cells (Figures S2A and S2B). To
completely separate the direct role of CD8 a+ DC and CD8+
T cells, specific antibody to CD8b chain or mice deficient of
CD8 a DC might be useful.
This essential role for T cells in antibody-mediated tumor
regression is not limited to the TUBO cell line. Anti-neu antibody
treatment of mice bearing neu-dependent N202 tumors, derived
from neu transgenic mice on the FVB background, also resulted
in tumor regression. More importantly, antibody-mediated tumor
regression of N202 tumor was also CD8+ T cell-dependent (data
not shown). As WT Balb/c mice are not tolerized to the neu
antigen, we decided to test whether CD8+ T cells contribute to
the effect of this antibody in a tolerant model. We used F1 neu
transgenic (Tg) mice (BALB/c x FVB/N MMTV-neu), which are
tolerant to the neu antigen and resistant to various treatments
(Machiels et al., 2001). Whereas TUBO bearing WT mice consis-
tently demonstrate tumor regression after anti-neu antibody
treatment, only 20% of tumors implanted in neu Tgmice demon-
strate complete regression with the other 80% relapsing a few
weeks after antibody cessation (Figure 3B). Nevertheless,
short-term treatment with the anti-neu antibody still resulted insignificant reduction of tumor growth in a CD8-dependent
fashion. Thus, tumor relapse in neu-Tg mice mimics frequently
relapse observed in the clinic. Therefore, in addition to support-
ing the role of CD8+ T cells in mediating neu-antibody therapy,
this data also raises an interesting possibility that anti-neu anti-
body may transiently break tolerance in neu-Tg mice and
generate immunity against HER2/neu+ tumors.
To determine whether the immune response initiated by anti-
neu antibody results in memory, the hallmark of adaptive immu-
nity, we evaluated cured mice for long-term protection by tumor
rechallenge. Mice that underwent complete tumor regression
following antibody treatment (n = 14) were rechallenged with
5 3 106 TUBO cells (10 times of the primary tumor inoculation)
after primary tumors had not been detected for at least 1 month.
Impressively, all mice rejected the rechallenged tumors (Fig-
ure 3C and Table 1). This data strongly supports the idea that
anti-neu antibody-mediated tumor regression generates detect-
able long-term immune memory capable of protecting the host
from rechallenge, and presumably against relapse.
To define whether tumor-specific T cell responses are
increased by antibody treatment, splenocytes were collected
after cessation of antibody treatment, and IFN-g production
from anti-neu or control antibody-treated TUBO bearing WT
mice was evaluated by ELISPOT. Antibody-treated group has
much higher neu-reactive T cells (Figure 3D). To further define
whether tumor-specific T cell responses are increased by anti-
body treatment, even in antibody-treated neu-Tg mice, the sple-
nocytes from Tg mice was evaluated by ELISPOT (Figure 3E).
In the antibody-treated group, 658 ± 133/106 neu-specific andCancer Cell 18, 160–170, August 17, 2010 ª2010 Elsevier Inc. 163
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Figure 4. Therapeutic Effect of Anti-Neu Antibody Depends on
Endogenous Danger Signals
(A) WT and Myd88/ BALB/c mice (n = 5–7/group) were injected s.c. with
4 3 105 TUBO cells and treated with 100 mg of anti-neu (a-neu) or isotype
control (Ctrl) antibody on days 21 and 28. *p < 0.01 compared to anti-neu anti-
body treated Myd88/ mice. One of two experiments is shown.
(B) TUBO-bearing WT BALB/c mice (n = 4/group) were treated with 100 mg of
anti-neu antibody (a-neu) and 100 mg of neutralizing anti-HMGB-1 antibody on
days 14 and 21. **p < 0.005, compared to anti-HMGB-1 antibody-treated
group. One of four experiments is shown.
Cancer Cell
Bridging Innate and Adaptive Immunity by Anti-Neu1475 ± 120.7/106 TUBO-specific IFN-g producing T cells were
detected in Tg mice, which was about 7–14-fold more than
control Ig-treated group. These data suggest that anti-neu anti-
body treatment induces neu- and TUBO-specific CD8+ T cell
responses.
To correlate this data with clinical observations, we compared
pre- and posttreatment breast tissue biopsies from patients with
HER2+ and HER2- tumors treated with trastuzumab and chemo-
therapy or chemotherapy alone respectively. There was no
significant difference in tumor-infiltrating lymphocytes (TIL)
between HER2+ versus HER2 tumor tissues before treatment,
with few cases having high TIL numbers before treatment. In
our medical center, obtaining paired pre- and post-antibody
samples is rare because trastuzumab treatment is reserved
mainly for patients with potential metastasis after primary tumors
have been surgically removed. However, we were able to obtain
multiple posttreatment samples and observed that primary
human HER2+ breast cancers had increased lymphocyte infil-
trates post trastuzumab treatment whereas no detectable
increase in lymphocyte infiltrates was observed in the chemo-
therapy alone group. Though both groups received chemo-
therapy, the addition of trastuzumab significantly increased
lymphocyte, especially CD8+ infiltrates (Figure S2C). Defining
the role of adaptive immunity initiated trastuzumab alone in
human studies will be challenging because standard care
requires that trastuzumab be combined with chemotherapy after
surgery, and additional biopsy of metastasis requires strict IRB
approval. Thus, formal clinical trials are needed to determine
whether and when trastuzumab alone can increase TIL in better
controlled cases.
Anti-Neu Antibody Induces HMGB-1 Release for Strong
Innate Responses
To test whether the MyD88 pathway is essential to tumor regres-
sion after antibody treatment, TUBO-bearing WT andMyd88/
mice were treated with anti-neu antibody. The therapeutic
effect of anti-neu antibody was abolished in Myd88/ mice
(Figure 4A). Recent studies have shown that HMGB-1 can
function as an endogenous danger signal that stimulates
DC cross-priming in a MyD88-dependent fashion (Apetoh
et al., 2007; Burgdorf et al., 2008). To determine whether anti-
body-mediated tumor regression is HMGB-1-dependent, free
HMGB-1 was neutralized by administration of an anti-HMGB-1
antibody (3B1) in conjunction with anti-neu antibody treatment.
Anti-HMGB-1 alone had no significant impact on tumor growth
(data not shown) whereas coinjection of anti-HMGB-1 antibody
partially diminished the therapeutic effects of anti-neu antibody
(Figure 4B). These data indicate that HMGB-1, an endogenous
danger signal, is essential for antibody-mediated tumor regres-
sion. It is conceivable that anti-neu antibody induces HMGB-1
release in the tumor microenvironment that enhances innate
responses via the MyD88 pathway.
Combination Treatments of Anti-Neu Antibody
with Chemotherapeutics
The essential role of T cells in anti-neu antibody-mediated tumor
regression warrants reevaluation of current anti-HER2/neu treat-
ment protocols because many current combination treatments
of antibody plus chemotherapy may have negative effects on164 Cancer Cell 18, 160–170, August 17, 2010 ª2010 Elsevier Inc.the host immune response to tumor antigens. For instance,
high dose chemotherapy is used clinically to significantly reduce
tumor burden; yet this treatment could possibly inhibit immune-
mediated tumor regression by limiting immune responses. To
test whether chemotherapy drugs used for breast cancer syner-
gize with or antagonize anti-neu antibody, this treatment was
combined with clinically equivalent doses of doxorubicin
(DOX), cyclophosphamide (CTX), or paclitaxel (PTX). These
chemotherapeutic agents are combined with anti-HER2/neu
antibody in the clinic and are effective for TUBO regression in
the presence or absence of antibody (Machiels et al., 2001).
CTX (100 mg/kg) or PTX (40–60 mg/kg) was administered
3–5 days after anti-neu antibody, and accelerated tumor mass
regression was observed compared to anti-neu antibody treat-
ment alone (Figures 5A and 5B and Table 1). On the contrary,
DOX treatment (5 or 15 mg/kg) concomitant with anti-neu anti-
body resulted in slower tumor regression than antibody alone,
and mice receiving this combined treatment demonstrated
tumor relapse whereas the antibody-alone treated group eradi-
cated tumors (Table 1). The lack of a strong effect by drugs is
not due to an insufficient dose, because the highest doses of
DOX (15 mg/kg) and PTX (60 mg/kg) increased morbidity and
mortality in a fraction of tumor bearing hosts (data not shown).
It was unclear whether the accelerated tumor regression
observed by combining anti-neu antibody treatment with CTX
or PTX was attributed to enhanced killing of tumor cells directly
by the chemotherapy or to enhance activation of the immune
system. To test the impact of chemotherapeutics on the immune
response and subsequent memory generated by anti-neu anti-
body treatment, micewere rechallengedwith 53 106 TUBOcells
(10 times more than primary tumor inoculum) 1–2 months after
tumor masses were undetectable. All mice whose primary tumor
underwent complete regression following anti-neu antibody
treatment alone rejected the tumor rechallenge (Table 1).
Surprisingly, amajority of themice treatedwith anti-neu antibody
and chemotherapy were susceptible to tumor rechallenge (66%
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Figure 5. Administration of Chemothera-
peutics after Antibody Treatment Enhances
Primary Tumor Reduction but Reduces
Immunity Induced by Anti-Neu Antibody
WT BALB/c mice (n = 5–10/group) were injected
s.c. with 5 3 105 TUBO cells and treated with
100 mg of anti-neu antibody (a-neu) on days 11
and 16. Select chemotherapeutic agents were
injected i.p. at different time points. One of three
experiments is shown. Reduced T cell proliferation
was seen in Figure S3.
(A) 100 mg/kg of CTX was injected i.p. on days 16,
23, and 33.
(B) 40 mg/kg of PTX was injected i.p. on days 14
and 19. Treated, tumor-free mice were rechal-
lenged with 2 3 106 TUBO cells when primary
tumor was not detected for at least 30 days.
(C) Percent tumor-bearing mice.
(D) Percent mean tumor volume.
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mice) (Figures 5C and 5D and Table 1). When a higher dose
(60 mg/kg) of PTX was used, the treated mice more effectively
controlled the growth of the primary tumor burden but were
less resistant to rechallenge (Figure 5D and Table 1). Although
the addition of chemotherapeutic agents induce a more robust
control of the primary tumor, they also confer a loss of protection
from tumor rechallenge, a potential problem related to late
relapse observed in the clinic once primary tumor is diminished
after treatment. Reduced white blood cell count is a common
side effect in patients undergoing chemotherapy. Although we
did not observe significant differences in the numbers or
percentages of T and B cells in blood, LN, and the spleen after
PTX treatment, the number of Ki67+ cells was reduced in PTX
treated group, suggesting early immune suppression (Figure S3).
We have previously shown that 20 mg/kg of PTX could suppress
the priming of antigen-specific CD8+ T cell response initiated
by local radiation of primary tumor (Lee et al., 2009). Similar
suppression of Ki67 on lymphocytes was detected in DOX
treated group (data not shown). CTX and DOX have been impli-
cated in immunosuppression leading to fulminant hepatitis B
hepatitis after chemotherapy for non-Hodgkin’s lymphoma in
an HBV carrier(Aomatsu et al., 2010). However, same drugs
can also boost immune responses, likely depending on doses
and patients’ immune status(Emens et al., 2001). More studies
are needed to address those complicated issues.
We speculated that theremight only be a window of timewhen
chemotherapy drugs may effectively reduce tumor burden
without inhibiting antibody-induced immunity, as the half-life of
these drugs is rather short. To test whether PTX given before
anti-neu antibody also inhibited immune memory, an identical
dose of PTX (40 mg/kg) was injected 24 hr before antibody
instead of 3 days after antibody treatment. Impressively, the
combination of PTX at this time and dose not only synergizedCancer Cell 18, 160–170with anti-neu antibody to control the
primary tumor, but also preserved the
ability of the host to clear a lethal tumor
rechallenge (Figures 6A and 6B and
Table 1). Therefore, a simple alterationof drug administration or dose could have a major impact on
the immunological memory response to tumor antigens. It is
likely that different doses and schedules related to drugs and
antibody as well as patient immune status might be critical for
overall antitumor effect, more studies, including animal models
and clinical trials, are needed to optimize the antitumor effects
by various protocols in the future.
Combination Treatments of Anti-Neu Antibody
with Ad-LIGHT
Although anti-neu antibody therapy induces initial immunity
against tumor, sustained immunity could be transient or dimin-
ished if the tumor is able to bolster immune suppressive mecha-
nisms. Onemajor hurdle for antibody treatment of an established
tumor is the tumor barrier that prevents effective infiltration of
antibody, FcR+ cells (NK and macrophages), DC, and T cells.
Expression of LIGHT intratumoral can attract various immune
cells, including substantial numbers of FcR+ cells, DC, and
T cells (Fan et al., 2006; Wang et al., 2005; Yu et al., 2004; Yu
et al., 2007). We reasoned, therefore, that given the necessity
of the adaptive immune system in anti-neu antibody therapy, tar-
geting tumors with an adenovirus expressing LIGHT (Ad-LIGHT)
by intratumoral injection could enhance tumor barrier break-
down, attract more immune cells, and amplify or sustain the ther-
apeutic effect of anti-neu antibody treatment. To test this
hypothesis and determine the contribution of Ad-LIGHT, mice
bearing established TUBO tumors (18 days after inoculation)
were treated with a suboptimal dose of anti-neu antibody in
close combination with intratumoral injection of Ad-LIGHT.
Neither suboptimal anti-neu antibody (two injections of
50 mg/mice), nor Ad-LIGHT alonewas sufficient to control tumors
(Figure S6A). Tumor growth in the Ad-LIGHT-treated group was
only delayed by 1–2 weeks, whereas all mice in the anti-neu anti-
body-treated group showed relapse 4–6 weeks after the end of, August 17, 2010 ª2010 Elsevier Inc. 165
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Figure 6. Administration of Chemotherapeutics before Antibody
Treatment Could Enhance Primary Tumor Reduction without
Affecting Immunological Memory
(A) WT BALB/c mice (n = 5–10/group) were injected s.c. with 5 3 105 TUBO
cells and treated with 40 mg/kg of PTX on day 10. Mice were then treated
with 100 mg of anti-neu antibody (a-neu) i.p. on days 11 and 18.
(B) Tumor-free mice from both groups were rechallenged with 5 3 106 TUBO
cells when primary tumor was not detected for at least 40 days. The growth of
tumor was measured twice a week. One of two representative experiments is
shown. Increase of antitumor immunity by antibody plus ad-LIGHTwas seen in
Figure S4.
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neu antibody and Ad-LIGHT resulted in rejection of all trans-
planted TUBO tumors, and no relapse was detected up to 8
weeks after the completion of treatment (Figure S4A). Notably,
this combination treatment generated immunity sufficient to
protect from lethal rechallenge of TUBO but not 4T1, a neu-
mammary carcinoma (Figure S4B), demonstrating that this
combination treatment induced neu-specific immunity. The
combination of anti-neu antibody and Ad-LIGHT was also tested
in neu Tg mice that frequently relapse after anti-neu antibody
single treatment. Impressively, the combination treatment of
anti-neu antibody and Ad-LIGHT rapidly controlled tumor growth
in 80% of tolerant mice, whereas neither of the single treatment
was able to control tumor growth effectively at the same dose
(Figures S4C and S4D). We believe these data support the
necessity of the adaptive immune system in anti-neu mediated
tumor regression and suggest that proper immunotherapy can
amplify or maintain antibody-initiated antitumor immunity to
clear residual cancer and prevent relapse, even in a tolerant envi-
ronment.
DISCUSSION
Over the past two decades, several studies aimed at under-
standing the mechanism(s) of anti-HER2/neu antibody therapy
have shown that this therapy can efficiently slow the growth of
HER2/neu+ tumors in vitro and in vivo, suggesting the impor-
tance of oncogenic signaling blockade in antibody-mediated
tumor reduction. However, FcR+ cells were also shown to be
essential for mediating the therapeutic effects of the HER2/neu
antibody (Clynes et al., 2000). Although not mutually exclusive,166 Cancer Cell 18, 160–170, August 17, 2010 ª2010 Elsevier Inc.these data promoted ADCC as the major mechanism for the
in vivo effects of antibody treatment. Here, we demonstrate
that T cells are necessary for the tumor reduction by anti-neu
antibody alone. Our current findings support the critical role of
T cells through the following findings: (1) the therapeutic effect
of HER2/neu antibody treatment on tumor growth is greatly
reduced in T cell-deficient mice; (2) WT mice depleted of CD8+
T cells show rapid relapse of tumor; (3) increased anti-neu reac-
tive T cells can be measured by ELISPOT after antibody treat-
ment; (4) antibody-treated, tumor-free mice are subsequently
resistant to high dose tumor rechallenge, suggesting the pres-
ence of immune memory; (5) increased T cell infiltration, espe-
cially CD8+ cells, can be detected in tumor tissue of mice treated
with anti-neu and patients treated with adjuvant HER2/neu
antibody, compared to untreated controls; and (6) CD8-depen-
dency occurs in both WT and tolerized neu-transgenic mice.
We believe this study reveals an essential role for the adaptive
immune system in the therapeutic effect of antibody treatment
on HER2/neu tumors.
The treatment of WT mice with anti-neu antibody did result in
more potent antitumor effects than treatment of neu-Tg mice.
Modeling human HER2+ cancer poses many complications.
On one hand, humans are partially tolerant to the HER2 tumor
antigen, so using neu transgenic mice provides an alternative
model. On the other hand, transgenic mice greatly overexpress
the neu antigen in every mammary epithelial cell soon after birth
and potentially induce stronger tolerance than that observed in
humans (Park et al., 2008). Endogenous anti-HER2 antibodies
have been detected and shown to suppress HER2 kinase activity
and to inhibit the transformed phenotype of HER2-expressing
tumor cells (Montgomery et al., 2005). Moreover, a recent study
demonstrated that treatment of neu transgenic mice with a
combination of anti-DR5 and anti-ErbB-2monoclonal antibodies
induced complete responses in a majority of the transgenic mice
(Park et al., 2008). Notably, depletion of CD8+ T cells provoked
primary and secondary tumor relapse, revealing the induction
of antitumor immunity by the combination treatment (Stagg
et al., 2008). Because anti-DR5 antibody mainly kills tumor cells,
this study raises the possibility that anti-neu antibody can also
induce immunity even in Tg mice. Therefore, using both WT
and transgenic models to assess anti-neu antibody treatment
of Her2/neu+ tumors is complementary .
Because FcR-deficient mice fail to reduce or eradicate tumor
after antibody treatment, ADCC was proposed as the ultimate
mechanism for tumor clearance. Our study, however, raises
the possibility that ADCC might not be the only mechanism
dependent on FcR+ cells. In addition to their cytotoxic effects,
FcR+ cells can also produce cytokines and/or danger signals in
response to signals received via FcR. Indeed, various FcR+ cells
can release HMGB-1 that increases cross-priming and activa-
tion of DC in both mice and humans (Apetoh et al., 2007;
Urbonaviciute et al., 2008). We have shown that the blockade
of even this one danger signal greatly reduces the efficacy of
antibody treatment. Thus, danger signals might coordinate
with FcR signaling to activate DC and NK cells. Furthermore,
APCs may use FcR to internalize antigens for enhanced presen-
tation. Several studies have shown that antitumor specific anti-
body treatment enhances cross-priming of CD8+ T cells through
FcR-mediated phagocytosis, especially through the formation of
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Ravetch, 2002; Rafiq et al., 2002). Given the importance of
danger signals in initiating immunity, we propose that blocking
oncogenic signals by the anti-HER2/neu antibody may be an
important initiator of, and positive-feedback loop for, adaptive
immunity. For instance, antibody treatment of a neu+ transfected
tumor line, that is not dependent on a HER2/neu signal for its
growth, does not reverse tumor growth in vitro and fails to
demonstrate any effect on in vivo tumor growth (Whittington
et al., 2008). We also observed that tyrosine kinase inhibitor
treatment is very potent in blocking oncogenic signals in vitro,
but anti-neu antibody is more potent in vivo, presumably
because of the additional FcR-mediated effect. More studies
are needed to explore the mechanisms and efficacy of the two
different treatment strategies to develop better combination
protocols.
Despite the initial clinical success of trastuzumab plus chemo-
therapy treatment for Her2+ tumors, in metastatic and adjuvant
settings, relapse still occurs. Frequently, this relapse is thought
to be acquired resistance to the antibody, but our data suggest
that this may also be the result of reduced T cell responses by
chemotherapy. It has been shown previously that agents tradi-
tionally used for tumor reduction can have both positive and
negative effects on host immunity (Emens et al., 2001). Most
conventional chemotherapeutic drugs inhibit rapidly dividing
cells, including some tumor cells and high proliferative T cells.
However, small numbers of tumor cells might undergo dormancy
or a very slow growth rate resulting in ‘‘drug resistance.’’ These
cells could be the source of relapse. Thus far, the traditional
combination of anti-HER2/neu antibody with chemotherapeutic
agents has shown additive and synergistic effects in in vitro
studies and in vivo xenograft tumor models (Hudis, 2007;
Pegram et al., 1999; Pegram et al., 2004). Chemotherapeutic
agents can not only reduce the size of the primary tumor, but
also alter immune responses. Recent studies showed that the
success of some protocols using low dose drug administration
for anticancer therapy might stimulate innate and adaptive
antitumor immune responses (Apetoh et al., 2007) or enhance
vaccine-mediated immunity (Emens et al., 2001). During low
dose chemotherapy, DCs require signaling through TLR4 and
its adaptor MyD88 for efficient processing and cross-presenta-
tion of antigen from dying tumor cells. Patients with breast
cancer who carry a Tlr4 loss-of-function allele relapse more
quickly after radiotherapy and chemotherapy than those carrying
the normal Tlr4 allele (Apetoh et al., 2007). Anti-neu antibody
treatment could play a unique role for combination with low
dose chemotherapy because it can significantly reduce tumor
burden while boosting immune responses. A recent study
showed that combined therapy with anti-DR5 and anti-ErbB-2
monoclonal antibodies significantly enhanced suppression of
the growth of advanced spontaneous tumors in ErbB-2/neuT
transgenic mice, even when treatment was delayed until tumors
were palpable (Stagg et al., 2008). Recent clinical study showed
that anti-HER-2/neu humoral responses significantly increased
during combinational chemo and trastuzumab therapy, support-
ing our clinical observation (Taylor et al., 2007). Thus, current
common uses of xenograft to evaluate antitumor effect by
various treatments and protocols have their limitation and could
have a biased selection of direct antitumor effect but ignoreimmune responses. As more preclinical and clinical studies are
conducted, taking immune responses into consideration for
future combination treatments will be necessary.
Based on numerous preclinical studies, clinical trials were
conducted and demonstrated benefits of chemotherapy admin-
istration with trastuzumab over chemotherapy alone. Thus, anti-
HER2/neu antibody therapy is currently administered in conjunc-
tion with chemotherapy. However, tests done by cell culture or
xenograph of human tumors into T cell deficient mice, may
have been biased in favor of high dose chemotherapy. It is
unclear whether chemotherapy plus anti-HER2/neu antibody is
always better than antibody alone (Hudis, 2007; Piccart-Gebhart
et al., 2005; Romond et al., 2005). Thus it remains to be deter-
mined if, when, and how anti-HER2/neu antibody should be
combined with chemotherapy. It is likely that careful monitoring
of the effect of chemotherapy on the tumor and the individual’s
immune response. Our study suggests that sequential adminis-
tration of anti-HER2/neu antibody after chemotherapy may allow
chemotherapy to enhance the antibody mediated antitumor
effect. Yet, formal clinical trials are needed to revisit this issue
and to address whether and which chemotherapy drugs can
enhance antibody mediated anti-cancer effect in neoadjuvant,
adjuvant, and metastasis settings.
Optimal impact of anti-neu antibody treatment on tumor
growth likely depends in part on the amount of antibody, and
the number of FcR+ cells antigen presenting cells inside the
tumor microenvironment. Therefore, combining this antibody
treatment with an immunotherapy that can break tumor barriers
and attract immune cells may have great impacts on the efficacy
of anti-HER2/neu antibody treatment. Ad-LIGHT has multiple
potential effects for enhancing antibody-mediated immunity.
We have previously shown that intratumoral delivery of LIGHT,
but not extra-tumoral delivery, can increase the expression of
chemokines and adhesion molecules within the tumor, which
then attract various immune cells, including T cells, NK, and
DC (Fan et al., 2006; Ishihara et al., 2004; Wang et al., 2005;
Yu et al., 2007). Recruiting FcR+ cells to the tumormight facilitate
the FcR-mediated effect of HER2/neu antibody. In addition,
LIGHT can also activate NK and T cells via the HVEM receptor
to enhance antitumor cytotoxicity (Fan et al., 2006). Finally,
driving high expression of LIGHT in the tumor by Ad-LIGHT
may elaborate lymphatic vessels and alter the permeability of
tumor vasculature to favor infiltration of both antibody and
immune cells. LTbR signaling on vessels has been shown to
promote the neogenesis of vasculature and regulate LN hyper-
trophy (Liao and Ruddle, 2006). Thus, the synergy we observe
from intratumoral injection of Ad-LIGHT during anti-neu antibody
treatment may result from increased infiltration of FcR+ cells and
enhanced interactions between antibody and FcR+ cells leading
to antibody-mediated tumor clearance and the generation and
local accumulation of T cells for the increase of host resistance
to rechallenge.
Our data demonstrate that T cells are necessary for anti-
HER2/neu antibody-mediated tumor reduction. Because the
antibodymediated blockade of oncogenic signals and the induc-
tion of ADCC have been previously demonstrated, we propose
that both of these outcomes can induce a significant release of
danger signals to alarm/activate DC and promote cytokine
production. FcR-mediated signaling can induce additionalCancer Cell 18, 160–170, August 17, 2010 ª2010 Elsevier Inc. 167
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tosis andMyD88-enhanced cross-presentation maymore effec-
tively activate the adaptive immune system for enhanced tumor
control. However, even with efficient blockade of oncogenic
signals and induction of proper danger signals, antibody-initi-
ated immunity may still be transient and weak, making further
combination immunotherapy necessary to reach clinical signifi-
cance. We demonstrate that timing of chemotherapeutic doses
has a distinct impact on antibody initiated immunity, and that
proper immunotherapy can synergize with antibody treatment.
Thus, this study provides insight into an interesting antitumor
mechanism of anti-HER2/neu antibody that promotes coopera-
tion between innate and adaptive immunity and warrants the use
of combination therapies promoting antibody-initiated antitumor
immune responses.
EXPERIMENTAL PROCEDURES
Mice
Balb/c, Balb/c Rag-1, and Rag-2 KO and FVB/N-Tg (MMTV-neu) mice were
purchased from Jackson Laboratory and Balb/c Fcrg/micewere purchased
from Taconic at 6 to 7 weeks of age. BALB/c MyD88/ mice were kindly
provided by Dr. Anita Chong, University of Chicago. Neu Tg F1 (FVB/N-Tg/
MMTV-neu 3 BALB/c) were bred and housed at the University of Chicago.
All mice were maintained under specific pathogen free conditions and used
between 6–16 weeks of age in accordance to the animal experimental guide-
lines set by the Institutional Animal Care and Use Committee. The study has
been approved by the Institutional Animal Care and Use Committee of the
University of Chicago and Institute of Biophysics and all experiments conform
to the relevant regulatory standards.
Cell Lines and Reagents
TUBO was cloned from a spontaneous mammary tumor in a BALB Neu Tg
mouse (Rovero et al., 2000), and N202 was cloned from a spontaneous
mammary tumor in a FBV Neu Tg mice. Both cell lines are gift from Joseph
Lustgarten (Mayo Clinic, Arizona). TUBO was cultured in 5% CO2, and main-
tained in vitro in DMEM supplemented with 10% heat-inactivated fetal bovine
serum (Sigma), 10% NCTC 109 medium, 2 mmol/l L-glutamine, 0.1 mmol/l
MEM nonessential amino acids, 100 units/ml penicillin, and 100 mg/ml strepto-
mycin.
APC 3T3/KB and 3T3/NKB were provided by Dr. Wei-Zen Wei, Wayne
State University (Wei et al., 2005). Anti-CD8 depleting antibody 53.6.7 was
purchased from BioXcell (West Lebanon, NH). Anti-neu mAb 7.16.4, anti-
CD8 depleting antibody YTS 169.4.2 (ATCC), and anti-HMGB-1 neutralizing
mAb 3B1, were produced in house. Anti-neu antibody (7.16.4) recognizes
the juxtamembranal region of rat neu and competes with 4D5, the precursor
of trastuzumab, for binding and inhibition of tumor growth (Zhang et al.,
1999). Anti-HMGB-1 mAb is capable of neutralizing HMGB-1 in vivo (Chen
et al., 2009). Chemotherapeutic agents including erlotinib (Tarceva; Genen-
tech, CA), cyclophosphamide (CTX; Baxter, IL), paclitaxel (PTX; Mayne
Pharma, NJ), and doxorubicin (DOX; Teva Parenteral Medicine, CA) were
purchased and prepared according to manufacturer recommendations. All
antibodies for FACS were purchased from BD Biosciences. The generation
of Ad-LIGHTwas described previously (Kim et al., 2007). Endotoxin inside anti-
body was measured by the limulus amebocyte lysate assay (Cambrex inc.
MD). For all mAb preparations, the amount of endotoxin was determined to
be <0.2 E.U./mg mAb (limit of detection).
In Vivo Treatments
TUBO cells (3–53 105) were injected subcutaneously (s.c.) in the back of 6- to
8-week-old mice. Tumor volumes were measured along three orthogonal axes
(a, b, and c) and calculated as tumor volume = abc/2. Mice were treated with
two or three intraperitoneal (i.p.) injections of 80–100 mg of anti-neu antibody
(7.16.4). For CD8 depletion experiments, 200 mg of anti-CD8 antibody (YTS
169.4.2 or 53.6.7) was injected i.p. at the same time as anti-neu antibody168 Cancer Cell 18, 160–170, August 17, 2010 ª2010 Elsevier Inc.treatment. For the HMGB-1 neutralizing experiment, 100 mg of mouse anti-
HMGB-1 antibody (3B1) was injected i.p. on the day of anti-neu antibody
treatment. For chemotherapeutic agent combination, 500 mg/mouse of erloti-
nib, 100 mg/kg of CTX, 40–60 mg/kg of PTX, or 5–15 mg/kg of DOX were
administered i.p. at the indicated times.
Proliferation Assay
Cell proliferation was measured indirectly by mitochondria metabolic
activity using amodified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium
bromide (MTT) assay. Briefly, quadruplicate wells of cells were plated in flat-
bottomed 96-well plates at 10,000 cells/well. Approximately 16 hr after plating,
when cells reached 40%–50% of confluence, dilutions of anti-neu mAb 7.16.4
or erlotinib were added. Replicate plates were terminated at 24 , 48 , and 72 hr
posttreatment. At each time point, 10–20 ml of 5 mg/ml MTT in PBS was added
and incubated for 4 hr at 37C before the stop reagent (isopropanol with
0.04 N HCl) was added and the absorbance measured at 600–650 nm.
Measurement of IFN-g–Secreting T Cells by ELISPOT Assay
Neu reactive T cells were measured by ELISPOT assay (Jacob et al., 2006).
In this assay, the APC were transfected to stably express the MHC-I molecule
H2-Kd and B7.1 (3T3KB) or H2-Kd, B7.1, and neu (3T3NKB), thus allowing for
measurement of neu-specific CD8+ T cell responses. Spleen or lymph node
cells (responder cells) were resuspended in RPMI 1640 supplemented with
10% FCS, 2 mmol/l L-glutamine, 100 units/ml penicillin, and 100 mg/ml strep-
tomycin. A total of 1–4 3 105 spleen or lymph node cells were added to each
well of a 96-well HTS IP plate (Millipore), which was precoated with 2.5 mg/ml
rat anti-mouse IFN-g (clone R4-6A2; BD-PharMingen). 3T3/NKB cells were
added as APC over the spleen cells. 3T3/KB cells were used as control. The
ratio of responder cells to APC was 10:1. After 48 hr of incubation, cells
were removed and 2 mg/ml biotinylated rat anti-mouse-IFN-g (clone XMG
1.2; BD-PharMingen) was added. Plates were incubated for another 12 hr at
4C, thenwashed to remove unbound antibody. Bound antibodywas detected
by incubating the plates with 0.9 mg/ml avidin-horseradish peroxidase
(BD-PharMingen) for 2 hr at room temperature. The substrate 3-amino-9-ethyl-
carbazole (AEC; PharMingen) diluted in 0.1 mol/l acetic acid and 0.003%
hydrogen peroxide was added, and the plate was incubated for 3–5 min.
AEC solution was discarded, and the plates were washed six times with water.
The visualized cytokine spots were enumerated with the ImmunoSpot analyzer
(CTL), and the results were expressed as the number of cytokine producing
cells per 106 cells.
Analysis of TIL
Tumor masses established by TUBO were resected 3 days after antibody.
For FACS analysis, single-cell suspensions were obtained by collagenase
digestion and incubated with fluorochrome-conjugated mAbs against surface
markers. Cells were acquired on FACSCanto flow cytometer (BD Cytometry
Systems). For immunohistochemical staining, resected tumors were
embedded in Tissue-Tek (Sakura Finetek, Netherlands) and snap frozen in
liquid nitrogen. The following primary antibodies were used for immunohisto-
chemistry of human tissues: CD4 (4B12; Leica Biosystems Newcastle
Ltd, UK), CD8 (C8/144B) and CD20cy (L26); DakoCytomation, Carpinteria,
CA. Immunostaining was performed on the automated Bond TM system (Le-
ica-Microsystems, Melbourne, Australia) according to the modified manufac-
turer protocol using Bond TM Polymer Refine Detection system (Leica
Biosystems Newcastle Ltd.). Peroxidase reaction was developed with 3,3
diaminobenzidine (DAB) provided in the kit.
Statistical Analysis
Differences between groups were analyzed using the two-tailed Student’s
t test or 2-way ANOVA. Error bars represent standard deviations (±SD).
For survival curves, differences between curves were analyzed using the
log-rank (Mantel-Cox) test.
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